Rifampicin

Generic Name: Rifampicin

Brand Names: Isonarif, Rifadin, Rifamate, Rifater, Rofact

Drug Type: Small Molecule

Chemical Formula: C_₄₃H_₅₈N_₄O_₁₂

CAS Number: 13292-46-1

Unique Ingredient Identifier: VJT6J7R4TR

Background: A semisynthetic antibiotic produced from Streptomyces mediterranei. It has a broad antibacterial spectrum, including activity against several forms of Mycobacterium. In susceptible organisms it inhibits DNA-dependent RNA polymerase activity by forming a stable complex with the enzyme. It thus suppresses the initiation of RNA synthesis. Rifampin is bactericidal, and acts on both intracellular and extracellular organisms. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p1160)

Indication: Rifampin is indicated for the treatment of tuberculosis and tuberculosis-related mycobacterial infections. In combination with pyrazinamide and isoniazid, it is used in the initial phase of the short-course treatment of pulmonary tuberculosis.

Associated Conditions: Cholestatic pruritus, MRSA Infections, Prosthetic Joint Infections, Asymptomatic Neisseria meningitidis carrier of the nasopharynx, Initial phase Tuberculosis, Late phase Tuberculosis

Associated Therapies: Antibacterial therapy

Clinical Trials

A Study to Evaluate the Effect of Cytochrome P450 (CYP) 3A Inhibitor (Itraconazole) and Inducer (Rifampin) on the Drug Levels of Golcadomide (BMS-986369) in Healthy Participants

Phase 1

Recruiting

Conditions: Healthy Volunteers

Interventions: Drug: Itraconazole
Drug: Rifampin
Drug: Golcadomide

First Posted Date: 2024-04-12

Last Posted Date: 2024-08-09

Lead Sponsor: Celgene

Target Recruit Count: 36

Registration Number: NCT06363630

Locations: 🇺🇸
Local Institution - 0002, Atlanta, Georgia, United States
🇺🇸
Local Institution - 0001, Lenexa, Kansas, United States

Study to Evaluate the Drug-drug Interaction of JMKX001899 in Healthy Subjects

Phase 1

Not yet recruiting

Conditions: Solid Tumor, Adult

Interventions: Drug: JMKX001899
Drug: Itraconazole
Drug: Rifampin
Drug: Midazolam
Drug: dextromethorphan
Drug: Rosuvastatin
Drug: digoxin

First Posted Date: 2024-04-04

Last Posted Date: 2024-04-04

Lead Sponsor: Jemincare

Target Recruit Count: 72

Registration Number: NCT06348290

A Study to Evaluate the Effect of Itraconazole and Rifampicin on the Pharmacokinetics of SY-5007 in Healthy Subjects

Phase 1

Not yet recruiting

Conditions: Healthy Subjects

Interventions: Drug: SY-5007
Drug: Itraconazole
Drug: Rifampin

First Posted Date: 2024-03-27

Last Posted Date: 2024-03-27

Lead Sponsor: Shouyao Holdings (Beijing) Co. LTD

Target Recruit Count: 28

Registration Number: NCT06332053

Locations: 🇨🇳
West China Hospital of Sichuan University, Chengdu, Sichuan, China

Studies Evaluating the Effects of Itraconazole or Rifampicin on the Pharmacokinetics of TY-9591 Tablets in Healthy Subjects

Phase 1

Completed

Conditions: NSCLC

Interventions: Drug: Itraconazole
Drug: Rifampicin

First Posted Date: 2024-02-13

Last Posted Date: 2024-12-30

Lead Sponsor: TYK Medicines, Inc

Target Recruit Count: 48

Registration Number: NCT06255951

Locations: 🇨🇳
Yali Liu, Guangdong, Shantou, China

Shortened Regimen for Drug-susceptible TB in Children

Phase 3

Recruiting

Conditions: Tuberculosis, Lymph Node
Mycobacterium Tuberculosis
Tuberculosis
Tuberculosis, Pulmonary

Interventions: Drug: Isoniazid
Drug: Pyrazinamide
Drug: Rifampin
Drug: Rifapentine
Drug: Moxifloxacin
Drug: Ethambutol

First Posted Date: 2024-02-12

Last Posted Date: 2025-05-13

Lead Sponsor: Johns Hopkins University

Target Recruit Count: 860

Registration Number: NCT06253715

Locations: 🇮🇳
Indian Council of Medical Research - National Institute for Research in Tuberculosis, Chennai, India
🇮🇳
Dr. D.Y. Patil Medical College, Hospital and Research Center, Pune, India
🇮🇩
Faculty of Medicine, Universitas Padjadjaran, Bandung, Indonesia

and more 4 locations